SILO Stock: Silo Pharma Adds to Its Scientific Advisory Board

Silo Pharma Inc (OTCMKTS: SILO) is setting the stage for a strong day in the market, following up on the tremendous gains seen out of the stock this morning. The company issued a press release this morning announcing that it has made yet another addition to its Scientific Advisory Board.

Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Skip to What You Want to Read

Silo Pharma Announces Addition to Its Scientific Advisory Board

In the press release, Silo Pharma announced that its Board of Directors has welcomed Dr. Charles B. Nemeroff, M.D., Ph.D., to its Scientific Advisory Board. 

Dr. Nemeroff is a clinical researcher and holds his position as Chair and Professor with the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin Dell Medical School. He is als the director of the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. 

In the release, SILO explained that before Dr. Nemeroff joined Dell Medical School, he held a position as Chair of the Department of Psychiatry and Behavioral Sciences and as Clinical Director of the Center on Aging at the University of Miami Miller School of Medicine. 

He has also served as President of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP). Moreover, he sits on the Board of the Brain and Behavioral Research Foundation. 

Finally, Dr. Nemeroff is a member of the National Academy of Medicine and President-elect of the Anxiety and Depression Association of America.  

Management Commentary

In a statement, Eric Weisblum, CEO at SILO, had the following to offer:

Dr. Nemeroff’s decades of clinical research in neuropsychiatric disorders and vast network of industry colleagues will be immensely helpful as we continue to pursue an increasing number of opportunities for investment in psychedelic drug research. 

The addition of Dr. Nemeroff rounds out a diverse body of researchers and critical thinkers on our Scientific Advisory Board. I look forward to working with Dr. Nemeroff and leveraging his perspective.

The understanding of psychedelic drugs for the treatment of emotional and behavioral disorders is increasing, but much research remains to be done. I look forward to applying Dr. Nemeroff’s years of research experience to the pursuit of new strategic opportunities for the company.

Why This Is Big News

The news released by Silo Pharma this morning proved to be overwhelmingly positive. Keep in mind, the company is working on ways to use psilocybin to treat some of the world’s most difficult-to-treat psychiatric conditions and neurodegenerative diseases. 

Not only is SILO one of only a handful of companies in the space, the company is already in Phase 2 development. 

At the same time, Silo Pharma is putting together an incredible Scientific Advisory Board, bringing some of the most well-respected medical professionals in the space into the frey. 

As the company continues to expand its Scientific Advisory Board, its probability of success in psychedelic medicine is only growing, creating a compelling opportunity for investors. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Final Thoughts

The bottom line here is simple. My confidence in Silo Pharma recently has been well placed. In the past month, the company has announced two new additions to its Scientific Advisory Board and a planned Phase 2 trial. 

At the same time, the stock is trading at an incredible undervaluation, especially considering how closely related it is to Mind Medicine (MMEDF), a stock with a market cap that just recently broke $1 billion. 

All in all, when we talk about SILO stock, we’re talking about a stock that represents a company on the leading edge of innovation in the psychedelic treatments space. At the same time, the company is putting together an incredible team of professionals that will help it maintain its leadership in the space. All in all, SILO stock is one to watch closely.